Alpha Tau Medical Ltd.

Symbol: DRTS




Market price today

  • -5.9021

    P/E Ratio

  • 0.0289

    PEG Ratio

  • 202.04M

    MRK Cap

  • 0.00%

    DIV Yield

Alpha Tau Medical Ltd. (DRTS) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Uzi Sofer
Full-time employees:121
Address:5 Kiryat Hamada Street

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Return on Investments

The company's asset efficiency, represented by a robust -0.272% return, is a testament to Alpha Tau Medical Ltd.'s adeptness in optimizing resource deployment. Alpha Tau Medical Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.319%. Furthermore, the proficiency of Alpha Tau Medical Ltd. in capital utilization is underscored by a remarkable -0.356% return on capital employed.

Stock Prices

Alpha Tau Medical Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.52, while its low point bottomed out at $2.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Alpha Tau Medical Ltd.'s stock market.

Liquidity Ratios

Analyzing DRTS liquidity ratios reveals its financial health of the firm. The current ratio of 1207.49% gauges short-term asset coverage for liabilities. The quick ratio (1196.27%) assesses immediate liquidity, while the cash ratio (222.60%) indicates cash reserves.

Current Ratio1207.49%
Quick Ratio1196.27%
Cash Ratio222.60%

Profitability Ratios

The effective tax rate stands at -0.05%, revealing its tax efficiency. The net income per EBT, 100.05%, and the EBT per EBIT, 81.67%, provide insights into its earnings hierarchy.

Effective Tax Rate-0.05%
Net Income per EBT100.05%
EBT per EBIT81.67%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 12.07, it details the span from stock purchase to revenue. The 12 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding1196
Days of Payables Outstanding591
Payables Turnover0.62

Cash Flow Ratios

The cash per share value, 1.22, showcases liquidity position.

Cash per Share1.22

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 6.21%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.08, we discern the balance between debt and equity financing. The long-term debt to capitalization, 6.23%, and total debt to capitalization, 7.32%, ratios shed light on its capital structure. An interest coverage of 74.64 indicates its ability to manage interest expenses.

Debt Ratio6.21%
Debt Equity Ratio0.08
Long Term Debt to Capitalization6.23%
Total Debt to Capitalization7.32%
Interest Coverage74.64
Company Equity Multiplier1.27

Per Share Data

Net income per share, -0.42, reflects the portion of profit attributed to each share. The book value per share, 1.22, represents the net asset value distributed per share, while the tangible book value per share, 1.22, excludes intangible assets.

Net Income Per Share-0.42
Book Value Per Share1.22
Tangible Book Value Per Share1.22
Shareholders Equity Per Share1.22
Interest Debt Per Share0.10
Capex Per Share-0.09

Growth Ratios

EBIT growth, -11.03%, and operating income growth, -11.03%, offer insights into operational profitability progression. The net income growth, 13.64%, showcases bottom-line expansion, and the EPS growth, 20.75%, measures the growth in earnings per share.

Gross Profit Growth-9.70%
EBIT Growth-11.03%
Operating Income Growth-11.03%
Net Income Growth13.64%
EPS Growth20.75%
EPS Diluted Growth20.75%
Weighted Average Shares Growth9.20%
Weighted Average Shares Diluted Growth9.20%
Operating Cash Flow Growth24.80%
Free Cash Flow Growth1.71%
10-Year Operating CF Growth per Share-153.30%
5-Year Operating CF Growth per Share-153.30%
3-Year Operating CF Growth per Share-44.34%
10-Year Net Income Growth per Share-235.76%
5-Year Net Income Growth per Share-235.76%
3-Year Net Income Growth per Share-91.32%
10-Year Shareholders Equity Growth per Share42761.27%
5-Year Shareholders Equity Growth per Share42761.27%
3-Year Shareholders Equity Growth per Share684.08%
Receivables Growth-98.27%
Inventory Growth100.00%
Asset Growth-10.62%
Book Value per Share Growth-26.78%
Debt Growth155.65%
R&D Expense Growth26.49%
SGA Expenses Growth-27.25%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 205,600,766, captures the company's total value, considering both debt and equity. Income quality, 0.62, assesses the reliability of reported earnings.

Enterprise Value205,600,766
Income Quality0.62
Capex to Operating Cash Flow35.64%
Capex to Depreciation-596.00%
Graham Number3.39
Return on Tangible Assets-27.15%
Graham Net Net0.89
Working Capital78,654,000
Tangible Asset Value84,475,000
Net Current Asset Value62,843,000
Average Receivables558,000
Average Payables1,994,500
Average Inventory-532,500
Days Payables Outstanding872

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.04, and the price to book ratio, 2.04, reflect the market's valuation relative to the company's book value.

Price Book Value Ratio2.04
Price to Book Ratio2.04
Price Earnings to Growth Ratio0.03
Enterprise Value Multiple-5.05
Price Fair Value2.04
Price to Tangible Book Ratio2.46
Enterprise Value Over EBITDA-5.94
EV to Operating Cash Flow-11.45
Earnings Yield-14.01%
Free Cash Flow Yield-11.70%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Alpha Tau Medical Ltd. (DRTS) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.902 in 2024.

What is the ticker symbol of Alpha Tau Medical Ltd. stock?

The ticker symbol of Alpha Tau Medical Ltd. stock is DRTS.

What is company IPO date?

IPO date of Alpha Tau Medical Ltd. is 2021-03-08.

What is company current share price?

Current share price is 2.900 USD.

What is stock market cap today?

The market cap of stock today is 202044740.000.

What is PEG ratio in 2024?

The current 0.029 is 0.029 in 2024.

What is the number of employees in 2024?

In 2024 the company has 121.